drugset / Trial / NCT05255276
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
Non-randomizedCrossoverOpen-labelOther
Summary
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.
Timeline
- Start
- 2022-02-02
- Primary completion
- 2022-05-12
- Completion
- 2023-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Itraconazole | Small molecule | 200 mg | — |
| Comparator | Rifampin | Small molecule | 600 mg | — |
| Comparator | Sitravatinib | Small molecule | 50 mg | — |
| Comparator | Sitravatinib | Small molecule | 100 mg | — |
Indications
No indication recorded.